Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY4050784 in Advanced Solid Tumors with SMARCA4/BRG1 Alterations
NCT06561685Phase 1Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2024
- Primary completion
- Oct 2027
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 1, open-label trial of FHD-909 in solid tumor and non-small cell lung cancer (NSCLC) (6 arms), sponsored by Eli Lilly and Company. Primary endpoints: Adverse Events at 48 months, Maximum Tolerated Dose at 48 months and 3 more. Started Sep 2024; status: recruiting.
02
Drugs
FHD-909
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06561685.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06561685.